Hepatoblastoma-The Evolution of Biology, Surgery, and Transplantation
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Dec 2018 · 1 min read
In brief
In brief
Comprehensive review of hepatoblastoma management covering molecular pathogenesis, risk stratification, and multimodal treatment approaches. Emphasizes surgical principles and the evolving role of liver transplantation in achieving >90% disease-free survival in favorable-risk patients, contextualized within the AHEP-1531 international study framework.
Written by the GCMD Library team from the article.
Statements in this article
Hepatoblastoma is the most common primary malignant liver tumor of childhood.
The incidence of hepatoblastoma has increased over the last 30 years.
Little is still known about the pathogenesis of hepatoblastoma.
Discoveries in molecular biology provide clues but have yet to define targeted therapies for hepatoblastoma.
Disease-free survival in hepatoblastoma varies according to stage.
Disease-free survival is greater than 90% in favorable risk hepatoblastoma populations.
Improved disease-free survival in hepatoblastoma is due in part to improvements in chemotherapeutic regimens, surgical resection, and earlier referral to liver transplant centers.